The Cryptosporidiosis drugs in development market research report provides comprehensive information on the therapeutics under development for Cryptosporidiosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cryptosporidiosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Cryptosporidiosis by seven companies/universities/institutes. The top development phase for Cryptosporidiosis is preclinical with four drugs in that stage. The Cryptosporidiosis pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Cryptosporidiosis pipeline products market are: Novartis, Oblita Therapeutics and Aviex Technologies.
The key targets in the Cryptosporidiosis pipeline products market include Calcium Dependent Protein Kinase 1.
The key mechanisms of action in the Cryptosporidiosis pipeline product include Calcium Dependent Protein Kinase 1 Inhibitor with one drug in Preclinical. The Cryptosporidiosis pipeline products include one routes of administration with the top ROA being Oral and three key molecule types in the Cryptosporidiosis pipeline products market including Small Molecule, and Recombinant Vector Vaccine.
Cryptosporidiosis overview
Cryptosporidiosis is an intestinal illness caused by a microscopic parasite called Cryptosporidium. Symptoms include watery diarrhea, dehydration, and lack of appetite, weight loss, fever, nausea, and vomiting. Risk factors include drinking contaminated water, animal handling, and being the parent of and infected child.
For a complete picture of Cryptosporidiosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
